Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Millennium: The Takeda Oncology Company and Therasis have formed a reseach collaboration, under which Therasis will use its proprietary technology, the Therasis Filter, to investigate and identify key properties of a portfolio of Millennium proprietary compounds.
Subscribe to our email newsletter
The Therasis Filter utilises a systems biology approach to characterise compound mechanism of action, compound-specific biomarkers for clinical development, and synergistic combinations for combination therapy through the construction and analysis of tumor-specific molecular interaction networks.
Millennium chief scientific officer Joseph Bolen said that the Therasis Filter represents an exciting systems biology approach with the potential to streamline the way oncology drugs are developed.
"We believe that understanding the networks of molecular interactions in specific cancer models using systems biology tools may facilitate the early identification of mechanism of action, biomarkers and synergistic drug combinations," Bolen said.